Responses
Technology (including: robots for production, incompatibilities, drug production and analytics, CRS)
TCH-052 Validation of an Automated Method For Compounding Monoclonal Antibody Patient Doses: Case Studies of Bevacizumab, Infliximab and Trastuzumab.
Compose a Response to This Article
Other responses
No responses have been published for this article.